West Pharma ups full year guidance

 

West Pharmaceutical beats Q1 2026 estimates with non-GAAP EPS $2.13 on $844.9M revenue, raises full-year 2026 guidance

• Q1 2026 net sales grew 21% YoY to $844.9M, while non-GAAP EPS increased 47% YoY to $2.13.
• Company guides Q2 2026 revenue range to $830–$850 million for the upcoming quarter.
• Raises full-year 2026 revenue guidance to $3.3–$3.35 billion and adjusted EPS guidance to $8.40–$8.75.

https://finviz.com/quote.ashx?t=WST&p=d